The GSA results, presented in Table 4, constitute the parameters deemed to be influential by PRCC, and the parameter lists are in decreasing order according to the magnitudes of the sensitivity measures
Coverage is usually limited to patients with type 2 diabetes who meet formulary and prior authorization requirements
7 In the phase 2 monotherapy trial these events were generally mild to moderate, most frequent during dose escalation, and tended to diminish with continued treatment
Side Effects and Safety Concerns with BPC-157 Clinical side effect data for BPC-157 remains extremely limited
The British Journal of Nutrition, 92 (4), 665-669
A methods brief format also supports continuity when the same compound is used across multiple projects, enabling labs to reduce repeated guesswork and improve consistency in how data is generated and interpreted